Between the multiple products moving from Phase 2 to 3 and looking to hit market soon, and the impending bull market, this BioTech Startup is poised to at least double by the beginning of February. There is going to be a lot more upside to CNTB in the coming year, and I believe we could see so much more than 2.00 CNTB
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.